Synlogic Stock Price, News & Analysis (NASDAQ:SYBX)

$12.12 +0.52 (+4.48 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$11.60
Today's Range$11.69 - $12.69
52-Week Range$8.76 - $23.00
Volume156,560 shs
Average Volume175,794 shs
Market Capitalization$261.26 million
P/E Ratio-2.61
Dividend YieldN/A
BetaN/A

About Synlogic (NASDAQ:SYBX)

Synlogic logoSynlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.

Receive SYBX News and Ratings via Email

Sign-up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:SYBX
CUSIPN/A
Phone+1-617-4019975

Debt

Debt-to-Equity RatioN/A
Current Ratio12.34%
Quick Ratio12.34%

Price-To-Earnings

Trailing P/E Ratio-2.60683760683761
Forward P/E Ratio-2.20
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$20.27 per share
Price / Book0.60

Profitability

Trailing EPS($4.68)
Net Income$-26,260,000.00
Net MarginsN/A
Return on Equity-50.19%
Return on Assets-46.76%

Miscellaneous

Employees9
Outstanding Shares21,410,000

Synlogic (NASDAQ:SYBX) Frequently Asked Questions

What is Synlogic's stock symbol?

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

When did Synlogic's stock split? How did Synlogic's stock split work?

Synlogic's stock reverse split on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

Where is Synlogic's stock going? Where will Synlogic's stock price be in 2018?

4 analysts have issued 1-year price targets for Synlogic's stock. Their forecasts range from $14.00 to $25.00. On average, they expect Synlogic's stock price to reach $18.75 in the next twelve months. View Analyst Ratings for Synlogic.

Who are some of Synlogic's key competitors?

Who are Synlogic's key executives?

Synlogic's management team includes the folowing people:

  • Michael F. Powell Ph.D., Chairman of the Board (Age 62)
  • Jose Carlos Gutierrez-Ramos Ph.D., President, Chief Executive Officer, Director
  • Todd Shegog, Chief Financial Officer, Secretary
  • Andrew W. Gengos, Chief Operating Officer - Head of Corporate Development (Age 53)
  • Paul Miller, Chief Scientific Officer
  • Jay Stoudemire Ph.D., Vice President - Preclinical Development, Regulatory and Quality Assurance
  • Aoife M. Brennan, Chief Medical Officer
  • Casi DeYoung, Chief Business Officer (Age 46)
  • Edward T. Mathers, Independent Director (Age 57)

Who owns Synlogic stock?

Synlogic's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Artal Group S.A. (3.38%), Millennium Management LLC (0.22%), Renaissance Technologies LLC (0.09%), Deutsche Bank AG (0.09%) and Spark Investment Management LLC (0.05%). View Institutional Ownership Trends for Synlogic.

Who sold Synlogic stock? Who is selling Synlogic stock?

Synlogic's stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Synlogic.

Who bought Synlogic stock? Who is buying Synlogic stock?

Synlogic's stock was purchased by a variety of institutional investors in the last quarter, including Artal Group S.A., Renaissance Technologies LLC, Deutsche Bank AG and Spark Investment Management LLC. View Insider Buying and Selling for Synlogic.

How do I buy Synlogic stock?

Shares of Synlogic can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Synlogic's stock price today?

One share of Synlogic stock can currently be purchased for approximately $12.12.

How big of a company is Synlogic?

Synlogic has a market capitalization of $261.26 million. The biotechnology company earns $-26,260,000.00 in net income (profit) each year or ($4.68) on an earnings per share basis. Synlogic employs 9 workers across the globe.

How can I contact Synlogic?

Synlogic's mailing address is 301 Binney St Ste 402, CAMBRIDGE, MA 02142-1030, United States. The biotechnology company can be reached via phone at +1-617-4019975 or via email at [email protected]


MarketBeat Community Rating for Synlogic (SYBX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  89 (Vote Outperform)
Underperform Votes:  101 (Vote Underperform)
Total Votes:  190
MarketBeat's community ratings are surveys of what our community members think about Synlogic and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Synlogic (NASDAQ:SYBX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.752.672.502.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.75$19.67$19.50$13.13
Price Target Upside: 94.30% upside93.38% upside4.11% upside9.86% downside

Synlogic (NASDAQ:SYBX) Consensus Price Target History

Price Target History for Synlogic (NASDAQ:SYBX)

Synlogic (NASDAQ:SYBX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/29/2018Piper Jaffray CompaniesInitiated CoverageOverweight -> Overweight$16.00HighView Rating Details
11/27/2017WedbushInitiated CoverageOutperform$20.00MediumView Rating Details
9/19/2017Leerink SwannInitiated CoverageOutperform -> Outperform$25.00LowView Rating Details
4/13/2017Cantor FitzgeraldReiterated RatingHold$14.00LowView Rating Details
11/15/2016HC WainwrightReiterated RatingHoldN/AView Rating Details
9/22/2016CitigroupLower Price TargetNeutral$31.50 -> $14.00N/AView Rating Details
9/21/2016OppenheimerDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Synlogic (NASDAQ:SYBX) Earnings History and Estimates Chart

Earnings by Quarter for Synlogic (NASDAQ:SYBX)

Synlogic (NASDAQ SYBX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017Q3 2017($0.50)($1.66)$0.10 million$0.11 millionViewN/AView Earnings Details
8/4/2017Q2 2017($3.15)ViewN/AView Earnings Details
5/9/2017Q1 2017($0.84)ViewN/AView Earnings Details
3/15/2017Q4 2016($2.94)ViewN/AView Earnings Details
11/10/2016Q3 2016($2.24)($1.82)ViewN/AView Earnings Details
8/15/2016Q2 2016($3.01)($1.89)ViewN/AView Earnings Details
5/12/2016Q1 2016($3.01)($2.24)ViewN/AView Earnings Details
11/13/2015Q3 2015($2.17)($0.56)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Synlogic (NASDAQ:SYBX) Earnings Estimates

Current Year EPS Consensus Estimate: $-5.5 EPS
Next Year EPS Consensus Estimate: $-2.77 EPS

Dividends

Dividend History for Synlogic (NASDAQ:SYBX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Synlogic (NASDAQ SYBX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 18.60%
Institutional Ownership Percentage: 50.30%
Insider Trades by Quarter for Synlogic (NASDAQ:SYBX)
Institutional Ownership by Quarter for Synlogic (NASDAQ:SYBX)

Synlogic (NASDAQ SYBX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/1/2016Jon IrvinVPSell280$1.43$400.407,625View SEC Filing  
11/1/2016Jon IrvinVPSell280$1.28$358.408,055View SEC Filing  
10/11/2016Jon IrvinVPSell150$1.83$274.508,335View SEC Filing  
10/3/2016Jon IrvinVPSell250$1.93$482.508,485View SEC Filing  
10/6/2015Michael PowellDirectorBuy857,142$7.00$5,999,994.00View SEC Filing  
10/6/2015Pfizer Incmajor shareholderBuy714,285$7.00$4,999,995.002,489,364View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Synlogic (NASDAQ SYBX) News Headlines

Source:
DateHeadline
Synlogic Inc (SYBX) Given Consensus Rating of "Hold" by BrokeragesSynlogic Inc (SYBX) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 23 at 3:16 AM
 Analysts Expect Synlogic Inc (SYBX) to Announce -$0.79 Earnings Per Share Analysts Expect Synlogic Inc (SYBX) to Announce -$0.79 Earnings Per Share
www.americanbankingnews.com - February 21 at 1:28 AM
Changes to its Board of Directors: Oryzon revamps its Board with an expert in Biomedicine and Epigenetics in the US industryChanges to its Board of Directors: Oryzon revamps its Board with an expert in Biomedicine and Epigenetics in the US industry
finance.yahoo.com - February 20 at 9:15 AM
Synlogic (SYBX) versus Argos Therapeutics (ARGS) Critical ReviewSynlogic (SYBX) versus Argos Therapeutics (ARGS) Critical Review
www.americanbankingnews.com - February 19 at 1:20 PM
Synlogic (SYBX) Presents At Leerink Partners 7th Annual Global Healthcare Conference - SlideshowSynlogic (SYBX) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 16 at 4:25 PM
Synlogic Presents Data from Immuno-Oncology Development Program Demonstrating Potent Anti-Tumor Immunity Following Administration of Novel STING Agonist-producing Synthetic Biotic™ MedicineSynlogic Presents Data from Immuno-Oncology Development Program Demonstrating Potent Anti-Tumor Immunity Following Administration of Novel STING Agonist-producing Synthetic Biotic™ Medicine
finance.yahoo.com - February 13 at 8:59 AM
Head to Head Survey: Synlogic (SYBX) and ChemoCentryx (CCXI)Head to Head Survey: Synlogic (SYBX) and ChemoCentryx (CCXI)
www.americanbankingnews.com - February 11 at 11:02 PM
Synlogic (SYBX) versus Baxalta (BXLT) Head to Head SurveySynlogic (SYBX) versus Baxalta (BXLT) Head to Head Survey
www.americanbankingnews.com - February 10 at 7:24 AM
Synlogic (SYBX) versus Novus Therapeutics (NVUS) Head to Head AnalysisSynlogic (SYBX) versus Novus Therapeutics (NVUS) Head to Head Analysis
www.americanbankingnews.com - February 8 at 5:22 PM
Synlogic to Present at the Leerink Partners 7th Annual Global Healthcare ConferenceSynlogic to Present at the Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 4:32 PM
$110,000.00 in Sales Expected for Synlogic Inc (SYBX) This Quarter$110,000.00 in Sales Expected for Synlogic Inc (SYBX) This Quarter
www.americanbankingnews.com - February 6 at 11:55 AM
Synlogic (SYBX) Downgraded to Strong Sell at ValuEngineSynlogic (SYBX) Downgraded to Strong Sell at ValuEngine
www.americanbankingnews.com - February 4 at 11:46 AM
-$0.79 EPS Expected for Synlogic Inc (SYBX) This Quarter-$0.79 EPS Expected for Synlogic Inc (SYBX) This Quarter
www.americanbankingnews.com - February 4 at 1:18 AM
Synlogic Announces Underwriters’ Option Exercise in FullSynlogic Announces Underwriters’ Option Exercise in Full
finance.yahoo.com - January 31 at 4:40 PM
Synlogic (SYBX) Stock Rating Lowered by Zacks Investment ResearchSynlogic (SYBX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 31 at 12:10 PM
Financial Comparison: Synlogic (SYBX) versus Cesca Therapeutics (KOOL)Financial Comparison: Synlogic (SYBX) versus Cesca Therapeutics (KOOL)
www.americanbankingnews.com - January 31 at 3:44 AM
Synlogic (SYBX) Receives New Coverage from Analysts at Piper Jaffray CompaniesSynlogic (SYBX) Receives New Coverage from Analysts at Piper Jaffray Companies
www.americanbankingnews.com - January 29 at 7:32 PM
Synlogic Inc (SYBX) Receives Consensus Recommendation of "Hold" from AnalystsSynlogic Inc (SYBX) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 29 at 9:24 AM
Peregrine Pharmaceuticals (CDMO) versus Synlogic (SYBX) Head-To-Head SurveyPeregrine Pharmaceuticals (CDMO) versus Synlogic (SYBX) Head-To-Head Survey
www.americanbankingnews.com - January 28 at 5:14 PM
Synlogic Announces Pricing of Public Offering of Common StockSynlogic Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - January 24 at 9:24 AM
Synlogic Announces Proposed Public Offering of Common StockSynlogic Announces Proposed Public Offering of Common Stock
finance.yahoo.com - January 23 at 4:15 PM
Financial Review: Synlogic (SYBX) & BioMarin Pharmaceutical (BMRN)Financial Review: Synlogic (SYBX) & BioMarin Pharmaceutical (BMRN)
www.americanbankingnews.com - January 21 at 3:24 AM
Synlogic (SYBX) Upgraded by Zacks Investment Research to HoldSynlogic (SYBX) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - January 20 at 2:38 PM
Comparing Kadmon (KDMN) and Synlogic (SYBX)Comparing Kadmon (KDMN) and Synlogic (SYBX)
www.americanbankingnews.com - January 14 at 5:34 PM
Critical Analysis: Synlogic (SYBX) & Kadmon (KDMN)Critical Analysis: Synlogic (SYBX) & Kadmon (KDMN)
www.americanbankingnews.com - January 8 at 1:30 AM
Synlogic Progresses Clinical and Preclinical Pipeline and Outlines 2018 CatalystsSynlogic Progresses Clinical and Preclinical Pipeline and Outlines 2018 Catalysts
finance.yahoo.com - January 5 at 8:57 AM
Zacks: Brokerages Anticipate Synlogic Inc (SYBX) Will Announce Earnings of -$0.78 Per ShareZacks: Brokerages Anticipate Synlogic Inc (SYBX) Will Announce Earnings of -$0.78 Per Share
www.americanbankingnews.com - January 1 at 7:28 AM
Zacks: Analysts Expect Mirna Therapeutics, Inc. (SYBX) Will Post Earnings of -$0.78 Per ShareZacks: Analysts Expect Mirna Therapeutics, Inc. (SYBX) Will Post Earnings of -$0.78 Per Share
www.americanbankingnews.com - December 15 at 1:34 PM
Blog Exposure - Synlogic And Ginkgo Bioworks Collaborate to Discover and Develop New Medicines for Neurological and Liver DisordersBlog Exposure - Synlogic And Ginkgo Bioworks Collaborate to Discover and Develop New Medicines for Neurological and Liver Disorders
finance.yahoo.com - December 11 at 9:30 AM
Synlogic, Inc. (SYBX) Announces Collaboration with Ginkgo Bioworks for New Neurological & Liver Disorder Discoveries and TreamentsSynlogic, Inc. (SYBX) Announces Collaboration with Ginkgo Bioworks for New Neurological & Liver Disorder Discoveries and Treaments
www.streetinsider.com - December 9 at 8:51 AM
Equities Analysts Set Expectations for Mirna Therapeutics, Inc.s FY2017 Earnings (SYBX)Equities Analysts Set Expectations for Mirna Therapeutics, Inc.'s FY2017 Earnings (SYBX)
www.americanbankingnews.com - November 30 at 6:30 AM
Mirna Therapeutics, Inc. (SYBX) Stock Rating Reaffirmed by WedbushMirna Therapeutics, Inc. (SYBX) Stock Rating Reaffirmed by Wedbush
www.americanbankingnews.com - November 28 at 12:36 AM
Zacks Investment Research Downgrades Mirna Therapeutics, Inc. (SYBX) to SellZacks Investment Research Downgrades Mirna Therapeutics, Inc. (SYBX) to Sell
www.americanbankingnews.com - November 22 at 6:46 AM
Mirna Therapeutics, Inc. to Post FY2017 Earnings of ($5.58) Per Share, Leerink Swann Forecasts (SYBX)Mirna Therapeutics, Inc. to Post FY2017 Earnings of ($5.58) Per Share, Leerink Swann Forecasts (SYBX)
www.americanbankingnews.com - November 17 at 8:08 PM
Synlogic Reports Third Quarter 2017 Financial Results and Recent ProgressSynlogic Reports Third Quarter 2017 Financial Results and Recent Progress
finance.yahoo.com - November 14 at 8:28 AM
Synlogic Reports Positive Top-Line Phase 1 Data Demonstrating Safety and Tolerability and Proof of Mechanism in Healthy Volunteers for SYNB1020, a Synthetic BioticTM Medicine for the Treatment of HyperammonemiaSynlogic Reports Positive Top-Line Phase 1 Data Demonstrating Safety and Tolerability and Proof of Mechanism in Healthy Volunteers for SYNB1020, a Synthetic BioticTM Medicine for the Treatment of Hyperammonemia
finance.yahoo.com - November 9 at 2:21 PM
Synlogic to Present at Upcoming Investor Conferences in NovemberSynlogic to Present at Upcoming Investor Conferences in November
finance.yahoo.com - November 9 at 2:21 PM
Synlogic Receives Orphan Drug Designation for SYNB1618, a Synthetic BioticTM Medicine for the Treatment of PhenylketonuriaSynlogic Receives Orphan Drug Designation for SYNB1618, a Synthetic BioticTM Medicine for the Treatment of Phenylketonuria
finance.yahoo.com - October 24 at 10:51 AM
Synlogic Strengthens Leadership Team with Appointment of Chief Operating Officer and Chief Human Resources OfficerSynlogic Strengthens Leadership Team with Appointment of Chief Operating Officer and Chief Human Resources Officer
finance.yahoo.com - October 11 at 8:15 AM
Mirna Therapeutics (SYBX) and Its Competitors Financial ComparisonMirna Therapeutics (SYBX) and Its Competitors Financial Comparison
www.americanbankingnews.com - October 6 at 4:28 AM
Biogen (BIIB) & Mirna Therapeutics (SYBX) Head to Head ContrastBiogen (BIIB) & Mirna Therapeutics (SYBX) Head to Head Contrast
www.americanbankingnews.com - September 29 at 10:02 AM
Financial Analysis: Mirna Therapeutics (SYBX) versus VIVUS (VVUS)Financial Analysis: Mirna Therapeutics (SYBX) versus VIVUS (VVUS)
www.americanbankingnews.com - September 28 at 2:28 PM
Kamada (KMDA) and Mirna Therapeutics (SYBX) Head to Head ReviewKamada (KMDA) and Mirna Therapeutics (SYBX) Head to Head Review
www.americanbankingnews.com - September 25 at 8:54 AM
Mirna Therapeutics (SYBX) versus Its Peers Head to Head AnalysisMirna Therapeutics (SYBX) versus Its Peers Head to Head Analysis
www.americanbankingnews.com - September 24 at 4:22 PM
Comparing Strongbridge Biopharma PLC (SBBP) & Mirna Therapeutics (SYBX)Comparing Strongbridge Biopharma PLC (SBBP) & Mirna Therapeutics (SYBX)
www.americanbankingnews.com - September 23 at 12:40 PM
Synlogic to Webcast Presentation at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-OncologySynlogic to Webcast Presentation at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
finance.yahoo.com - September 23 at 9:39 AM
Mirna Therapeutics, Inc. Forecasted to Earn FY2017 Earnings of ($3.20) Per Share (SYBX)Mirna Therapeutics, Inc. Forecasted to Earn FY2017 Earnings of ($3.20) Per Share (SYBX)
www.americanbankingnews.com - September 21 at 8:42 AM
Leerink Swann Comments on Mirna Therapeutics, Inc.s Q3 2017 Earnings (SYBX)Leerink Swann Comments on Mirna Therapeutics, Inc.'s Q3 2017 Earnings (SYBX)
www.americanbankingnews.com - September 20 at 6:36 AM
Mirna Therapeutics, Inc. (SYBX) Earns Outperform Rating from Analysts at Leerink SwannMirna Therapeutics, Inc. (SYBX) Earns Outperform Rating from Analysts at Leerink Swann
www.americanbankingnews.com - September 19 at 8:58 AM
Mirna Therapeutics (SYBX) and Its Competitors Financial AnalysisMirna Therapeutics (SYBX) and Its Competitors Financial Analysis
www.americanbankingnews.com - September 17 at 10:16 AM

SEC Filings

Synlogic (NASDAQ:SYBX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Synlogic (NASDAQ:SYBX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Synlogic (NASDAQ SYBX) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.